Cariprazine Exhibits Anxiolytic and Dopamine D(3) Receptor-Dependent Antidepressant Effects in the Chronic Stress Model

BACKGROUND: Cariprazine, a D(3)-preferring dopamine D(2)/D(3) receptor partial agonist, is a new antipsychotic drug recently approved in the United States for the treatment of schizophrenia and bipolar mania. We recently demonstrated that cariprazine also has significant antianhedonic-like effects i...

Descripción completa

Detalles Bibliográficos
Autores principales: Duric, Vanja, Banasr, Mounira, Franklin, Tina, Lepack, Ashley, Adham, Nika, Kiss, Béla, Gyertyán, István, Duman, Ronald S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Regular Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632312/
https://www.ncbi.nlm.nih.gov/pubmed/28531264
http://dx.doi.org/10.1093/ijnp/pyx038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632312/
https://www.ncbi.nlm.nih.gov/pubmed/28531264
http://dx.doi.org/10.1093/ijnp/pyx038

Ejemplares similares